NEW YORK, April 13, 2023 /PRNewswire/ -- The motion sickness drugs market size is forecasted to increase by USD 119.64 million from 2021 to 2026, at a CAGR of 4.15%, according to the recent market study by Technavio. The growth of the market will be driven by the availability of over-the-counter (OTC) drugs, the availability of drugs in multiple dosage forms, and growing tourism worldwide. Get a comprehensive report summary describing the market size and forecast along with research methodology. Download the Sample Report
Vendor Analysis
The global motion sickness drugs market is fragmented due to the presence of several large and small players that offer branded and generic motion sickness drugs. Considering the patent expiry of major drugs over the past few years, generic players have a significant role in the market, which has intensified the competition among vendors in the market. The global motion sickness drugs market is currently witnessing an increasing demand-supply imbalance. To fill this gap, the US FDA has listed a scopolamine transdermal patch on its drug shortage list. The market has witnessed the entry of generic players that could cater to the rising demand for scopolamine. However, these players have opted out of motion sickness drug manufacturing. Considering the high demand-supply imbalance, the market is anticipated to witness the entry of new players during the forecast period, which will further intensify the competition among vendors. Some of the key vendors covered in the report include:
- Aurobindo Pharma Ltd
- Baxter International Inc.
- Caleb Pharmaceuticals Inc
- Cipla Ltd.
- CVS Health Corp.
- DM Pharma
- Dr. Reddy's Laboratories Ltd
- GlaxoSmithKline Plc
- Hylands
- Johnson & Johnson
- Lupin Ltd
- Merck KGaA
- Myungmoon Pharm Co. Ltd.
- Perrigo Co. Plc
- Pfizer Inc.
- Prestige Consumer Healthcare Inc.
- Reliefband Technologies LLC
- Viatris Inc.
- WellSpring Pharmaceutical Corp.
- Zenomed Healthcare Pvt. Ltd
Why Buy?
- Add credibility to strategy
- Analyzes competitor's offerings
- Get a holistic view of the market
Grow your profit margin with Technavio - Buy the Report
Key Benefits for Industry Players & Stakeholders –
- The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
- It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
- The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Get a holistic overview of the motion sickness drugs market from industry experts to evaluate and develop growth strategies. Download the Sample
Market Segmentation:
The market is segmented by product (anticholinergics and antihistamines) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).
- The market growth in anticholinergics will be significant during the forecast period. The segment is driven by the use of anticholinergic drugs such as hyoscine hydrobromide or scopolamine for the prevention of motion sickness. Hyoscine is one of the most potent drugs used for the prophylaxis of motion sickness. It is a naturally occurring alkaloid that competitively binds to muscarinic receptors and inhibits the release of acetylcholine. It can penetrate the blood-brain barrier (BBB) due to its lipophilic nature, thus exhibiting both central as well as parasympathetic effects. Such factors are driving the growth of the segment.
- North America will account for 41% of the market growth during the forecast period. The growth of the regional market is driven by the presence of large pharmaceutical companies that offer both branded and generic motion sickness drugs. The presence of a proper regulatory framework for the approval of new drugs is also contributing to the growth of the motion sickness drugs market in North America.
Market Dynamics:
Key Drivers:
- Availability of over-the-counter (OTC) drugs
- Availability of drugs in multiple dosage forms
- Growing tourism worldwide
The market has several branded as well as generic OTC drugs for the treatment of motion sickness. There are several antihistamines available as OTC drugs for the prevention of symptoms of motion sickness. These drugs are sold directly to patients without the need for a prescription from a healthcare professional. This has increased the accessibility and the freedom of self-medication for the treatment of symptoms associated with minor illnesses. The availability of OTC drugs has also reduced the financial burden associated with medication, as it eliminates the need for a prescription. Many such benefits are increasing the availability as well as the sales of OTC drugs for the treatment of motion sickness, which is driving the growth of the market.
Major Trends:
- Advent of nauseogenic information technology
- Rising trend of virtual reality
- Growing research on psychosomatic disorders
The advent of nauseogenic information technology has increased the understanding of neurophysiology and the parts of the brain involved in motion sickness. The technology has provided vital insights for the future development of effective drugs for the treatment of the condition. The research and application of this technology in this area are currently in their early stages. Further advances in nauseogenic information technology are expected to result in the development of effective drugs, which will positively impact the growth of the market.
Key Challenges:
- Non-pharmacological countermeasures to treat motion sickness
- Launch of generics
- Side-effects associated with motion sickness drugs
There are several non-pharmacological substitutes for the treatment of motion sickness. For example, habitual training involves exposing the subject to prolonged periods of motion stimulation. The training can last for up to several weeks. Repeated exposure to motion simulation can be beneficial in achieving the linear acceleration of acquiring motion sickness habituation. Some studies have revealed that preflight virtual reality training is also helpful in overcoming motion sickness. Other habituation training methods include the use of a revolving chair, winding stair, idler wheel, and swings. Similarly, behavioral training involves the use of a forward-looking vision to a distant horizon to alleviate the symptoms of motion sickness in individuals. Thus, the availability of such non-pharmacological countermeasures will challenge the growth of the market.
Gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
What are the key data covered in this motion sickness drugs market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the motion sickness drugs market between 2022 and 2026
- Precise estimation of the size of the motion sickness drugs market and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the motion sickness drugs market industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of motion sickness drugs market vendors
Related Reports:
- The pulmonary arterial hypertension (PAH) drugs market size is estimated to grow at a CAGR of 6.62% between 2022 and 2027. The market size is forecasted to increase by USD 2,080.07 million. It is segmented by route of administration (oral, injectable, and inhalation), action mechanism (prostacyclin analogs, endothelin receptor antagonists (ERAS), phosphodiesterase (PDE) inhibitors, and soluble guanylate cyclase stimulators (SGCSS)), and geography (North America, Europe, Asia, and Rest of World (ROW)).
- The obsessive-compulsive disorder drugs market size is expected to increase by USD 266.78 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.55%. The market is segmented by product (SSRI, TSA, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Motion Sickness Drugs Market Scope |
|
Report Coverage |
Details |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.15% |
Market growth 2022-2026 |
USD 119.64 million |
Market structure |
Fragmented |
YoY growth 2021-2022 (%) |
3.67 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aurobindo Pharma Ltd, Baxter International Inc., Caleb Pharmaceuticals Inc, Cipla Ltd., CVS Health Corp., DM Pharma, Dr Reddys Laboratories Ltd, GlaxoSmithKline Plc, Hylands, Johnson and Johnson, Lupin Ltd, Merck KGaA, Myungmoon Pharm Co. Ltd., Perrigo Co. Plc, Pfizer Inc., Prestige Consumer Healthcare Inc., Reliefband Technologies LLC, Viatris Inc., WellSpring Pharmaceutical Corp., and Zenomed Healthcare Pvt. Ltd |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse through Technavio's Health Care Market Reports
Table of contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Product
- 5.1 Market segments
- Exhibit 24: Chart on Product - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
- 5.2 Comparison by Product
- Exhibit 26: Chart on Comparison by Product
- Exhibit 27: Data Table on Comparison by Product
- 5.3 Anticholinergics - Market size and forecast 2021-2026
- Exhibit 28: Chart on Anticholinergics - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Anticholinergics - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Anticholinergics - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Anticholinergics - Year-over-year growth 2021-2026 (%)
- 5.4 Antihistamines - Market size and forecast 2021-2026
- Exhibit 32: Chart on Antihistamines - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Antihistamines - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Antihistamines - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Antihistamines - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Product
- Exhibit 36: Market opportunity by Product ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Canada - Market size and forecast 2021-2026
- Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 China - Market size and forecast 2021-2026
- Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.11 Germany - Market size and forecast 2021-2026
- Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Baxter International Inc.
- Exhibit 85: Baxter International Inc. - Overview
- Exhibit 86: Baxter International Inc. - Business segments
- Exhibit 87: Baxter International Inc. - Key news
- Exhibit 88: Baxter International Inc. - Key offerings
- Exhibit 89: Baxter International Inc. - Segment focus
- 10.4 Caleb Pharmaceuticals Inc
- Exhibit 90: Caleb Pharmaceuticals Inc - Overview
- Exhibit 91: Caleb Pharmaceuticals Inc - Product / Service
- Exhibit 92: Caleb Pharmaceuticals Inc - Key offerings
- 10.5 GlaxoSmithKline Plc
- Exhibit 93: GlaxoSmithKline Plc - Overview
- Exhibit 94: GlaxoSmithKline Plc - Business segments
- Exhibit 95: GlaxoSmithKline Plc - Key offerings
- Exhibit 96: GlaxoSmithKline Plc - Segment focus
- 10.6 Johnson and Johnson
- Exhibit 97: Johnson and Johnson - Overview
- Exhibit 98: Johnson and Johnson - Business segments
- Exhibit 99: Johnson and Johnson - Key news
- Exhibit 100: Johnson and Johnson - Key offerings
- Exhibit 101: Johnson and Johnson - Segment focus
- 10.7 Myungmoon Pharm Co. Ltd.
- Exhibit 102: Myungmoon Pharm Co. Ltd. - Overview
- Exhibit 103: Myungmoon Pharm Co. Ltd. - Product / Service
- Exhibit 104: Myungmoon Pharm Co. Ltd. - Key offerings
- 10.8 Perrigo Co. Plc
- Exhibit 105: Perrigo Co. Plc - Overview
- Exhibit 106: Perrigo Co. Plc - Business segments
- Exhibit 107: Perrigo Co. Plc - Key offerings
- Exhibit 108: Perrigo Co. Plc - Segment focus
- 10.9 Pfizer Inc.
- Exhibit 109: Pfizer Inc. - Overview
- Exhibit 110: Pfizer Inc. - Product / Service
- Exhibit 111: Pfizer Inc. - Key news
- Exhibit 112: Pfizer Inc. - Key offerings
- 10.10 Prestige Consumer Healthcare Inc.
- Exhibit 113: Prestige Consumer Healthcare Inc. - Overview
- Exhibit 114: Prestige Consumer Healthcare Inc. - Business segments
- Exhibit 115: Prestige Consumer Healthcare Inc. - Key offerings
- Exhibit 116: Prestige Consumer Healthcare Inc. - Segment focus
- 10.11 Reliefband Technologies LLC
- Exhibit 117: Reliefband Technologies LLC - Overview
- Exhibit 118: Reliefband Technologies LLC - Product / Service
- Exhibit 119: Reliefband Technologies LLC - Key offerings
- 10.12 WellSpring Pharmaceutical Corp.
- Exhibit 120: WellSpring Pharmaceutical Corp. - Overview
- Exhibit 121: WellSpring Pharmaceutical Corp. - Product / Service
- Exhibit 122: WellSpring Pharmaceutical Corp. - Key offerings
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 123: Inclusions checklist
- Exhibit 124: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 125: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 126: Research methodology
- Exhibit 127: Validation techniques employed for market sizing
- Exhibit 128: Information sources
- 11.5 List of abbreviations
- Exhibit 129: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article